Dr. Bingham has received consulting fees (less than $10,000) from Procter & Gamble. Dr. Cohen has received consulting fees and/or honoraria (less than $10,000) from Procter & Gamble. Dr. Dougados has received consulting fees and/or honoraria (less than $10,000) from Procter & Gamble. Dr. Adami has received consulting fees and/or honoraria (less than $10,000) from Procter & Gamble. Dr. Spector has received consulting fees and/or honoraria (more than $10,000) from Procter & Gamble. Dr. Strand has served as a consultant to and/or has received honoraria (less than $10,000 each) from Abbott Immunology, Amgen, Biogen Idec, Can-Fite BioPharma Ltd., Celera, Centocor, Chelsea Therapeutics, Coley Pharmaceutical Group, Cypress Pharmaceutical, FibroGen, Genelabs Technologies, Genentech, Human Genome Sciences, Immunomedics, Incyte Pharmaceuticals, Millennium Pharmaceuticals, Novartis, Omeros, Pfizer, Procter & Gamble, Rigel Pharmaceuticals, Roche, Sanofi Aventis, Schering-Plough, Scios, Serono, Sanwa Kagaku Kenkyusho Ltd., Sumitomo, UCB Pharma, XDx, and Xencor. Additionally, Dr. Strand serves on advisory boards for Abbott Immunology, Alder Biopharmaceuticals, Amgen, BioSeek, CanFite BioPharma, Centocor, Chelsea Therapeutics, Jazz Pharmaceuticals, Novartis, Pfizer, Robert Wood Johnson Pharmaceutical Research Institute, Roche, Sanofi-Aventis, Savient Pharmaceuticals, UCB Pharma, and Wyeth, and serves on speaking bureaus for Abbott Immunology, Amgen, Centocor, Novartis, Pfizer, and Santofi-Adventis.
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: Results of the two-year multinational knee osteoarthritis structural arthritis study
Article first published online: 30 OCT 2006
Copyright © 2006 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 54, Issue 11, pages 3494–3507, November 2006
How to Cite
Bingham, C. O., Buckland-Wright, J. C., Garnero, P., Cohen, S. B., Dougados, M., Adami, S., Clauw, D. J., Spector, T. D., Pelletier, J.-P., Raynauld, J.-P., Strand, V., Simon, L. S., Meyer, J. M., Cline, G. A. and Beary, J. F. (2006), Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: Results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis & Rheumatism, 54: 3494–3507. doi: 10.1002/art.22160
- Issue published online: 30 OCT 2006
- Article first published online: 30 OCT 2006
- Manuscript Accepted: 11 JUL 2006
- Manuscript Received: 31 JAN 2006
- 7ECHODIAH nvestigators Study Group. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Arthritis Rheum 2001; 44: 2539–47., , , , , , for the
- 17Risedronate but not alendronate slows disease progression in the guinea pig model of primary osteoarthritis [abstract]. J Bone Miner Res 2001; 16 Suppl 1: SA472., , .
- 18Bisphosphonates structurally similar to risedronate (actonel) slow disease progression in the guinea pig model of primary osteoarthritis [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S307., , , , .
- 19The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 2004; 50: 1193–206., , , , , , et al.
- 29European Corticosteroid-Induced Osteoporosis Treatment Study. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000; 15: 1006–13., , , , , , et al, for the
- 31Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986; 29: 1039–49., , , , , , et al, for the
- 39Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum 2001; 45: 384–91., , .
- 42Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 2004; 63: 931–9., , , , , , et al.
- 45Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. J Rheumatol 2004; 31: 150–6., , , , .
- 46Quantitative measurements of joint space during progression of osteoarthritis: “chondrometry.” In: KuettnerK, GoldbergV, editors. Osteoarthritic disorders. Rosemont (IL): American Academy of Orthopaedic Surgeons; 1995. p. 427–44..
- 49Progression of joint space narrowing in knee osteoarthritis [abstract]. Arthritis Rheum 1992; 35 Suppl 9: S134., , , , , .
- 54Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002; 46: 2847–56., , , , , , et al.
- 60Predictors of structural progression in knee osteoarthritis over 24 months [abstract]. Osteoarthritis Cartilage 2004; 12 Suppl B: S136., , , , , , et al.